Blog

From mobile devices to wearables and biosensors, digital innovation has led to an exponential increase in the availability of health-related data. While the healthcare market has traditionally been slow to adopt digital innovations (in 2017 14% of US clinician offices still relied on paper medical records) there are now a multitude of ways healthcare companies...

As public and political scrutiny of drug prices continues, pharmaceutical companies are increasingly encountering new governmental efforts to control rising drug costs. At the federal level, this scrutiny resulted in the publication of the Trump administration’s American Patients First blueprint last year. While the major...

With the recent publication of American Patients First, the Trump administration has provided what it describes as a “blueprint to lower drug prices and reduce patient out-of-pocket costs.” Less a blueprint than a general position document, American Patients First is light on details and heavy...

Determining the right price for a drug involves analyzing multiple variables and carefully articulating value to stakeholders.  Here’s a big-picture view of the process. Pricing pharmaceuticals is not only complex, involving multiple variables and affecting numerous stakeholders, it’s also intensely politically sensitive. Increasing scrutiny of the...

Jupiter helps biotech innovators build custom optimal market access and pricing solutions tailored to local market dynamics and payer requirements  As we continue to expand our presence globally, the breadth of Jupiter’s experience with companies throughout the world uniquely qualifies us to help biotech innovators...

BOSTON – Dec. 12, 2017 – Jupiter Life Science Consulting, a global leader in market access and pricing strategy in the biopharmaceutical industry, today announced the acquisition of Alta Bioscience Consulting. Alta is a global provider of advisory services in the development and commercialization of...